CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from Alliance A031203 trial Meeting Abstract
| Authors: | Choueiri, T. K.; Halabi, S.; Sanford, B.; Hahn, O.; Michaelson, M. D.; Walsh, M.; Olencki, T.; Picus, J.; Small, E. J.; Dakhil, S.; George, D.; Morris, M. J. |
| Abstract Title: | CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from Alliance A031203 trial |
| Meeting Title: | 41st European Society for Medical Oncology Congress (ESMO) |
| Journal Title: | Annals of Oncology |
| Volume: | 27 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2016 Oct 7-11 |
| Meeting Location: | Copenhagen, Denmark |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2016-10-01 |
| Start Page: | vi566 |
| Language: | English |
| ACCESSION: | WOS:000393913000712 |
| DOI: | 10.1093/annonc/mdw435.23 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA30_PR -- Source: Wos |
